Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Axogen, Inc., Globus Medical or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Axogen, Inc., Globus Medical and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Axogen, Inc., Globus Medical and Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Latest Health Care Equipment & Supplies and Axogen, Inc., Globus Medical, Inc. Stock News

As of October 9, 2026, Axogen, Inc. had a $2.1 billion market capitalization, compared to the Health Care Equipment & Supplies median of $385.5 million. Axogen, Inc.’s stock is up 10.5% in 2026, down 2.8% in the previous five trading days and up 110.55% in the past year.

Currently, Axogen, Inc. does not have a price-earnings ratio. Axogen, Inc.’s trailing 12-month revenue is $251.2 million with a -13.4% net profit margin. Year-over-year quarterly sales growth most recently was 22.9%. Analysts expect adjusted earnings to reach $0.474 per share for the current fiscal year. Axogen, Inc. does not currently pay a dividend.

As of October 9, 2026, Globus Medical, Inc. had a $10.0 billion market cap, putting it in the 78th percentile of all stocks. Globus Medical, Inc.’s stock is down 13.5% in 2026, down 1.3% in the previous five trading days and up 23.55% in the past year.

Currently, Globus Medical, Inc.’s price-earnings ratio is 19.1. Globus Medical, Inc.’s trailing 12-month revenue is $3.1 billion with a 17.0% net profit margin. Year-over-year quarterly sales growth most recently was 5.9%. Analysts expect adjusted earnings to reach $5.000 per share for the current fiscal year. Globus Medical, Inc. does not currently pay a dividend.

How We Compare Axogen, Inc., Globus Medical and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Axogen, Inc., Globus Medical and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Axogen, Inc., Globus Medical and Inc. Stock Value Grades

Company	Ticker	Value
Axogen, Inc.	AXGN	F
Globus Medical, Inc.	GMED	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Axogen, Inc. has a Value Score of 3, which is Ultra Expensive. Globus Medical, Inc. has a Value Score of 49, which is Average.

The Value Stock Winner: No Clear Winner

Neither Axogen, Inc., Globus Medical or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Axogen, Inc., Globus Medical or Inc. is the better investment when it comes to value.

Axogen, Inc., Globus Medical and Inc.’s Momentum Grades

Company	Ticker	Momentum
Axogen, Inc.	AXGN	A
Globus Medical, Inc.	GMED	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Axogen, Inc. has a Momentum Score of 92, which is Very Strong. Globus Medical, Inc. has a Momentum Score of 73, which is Strong.

The Momentum Grade Winner: Axogen, Inc.

As you can clearly see from the Momentum Grade breakdown above, Axogen, Inc. is considered to have stronger momentum compared to Globus Medical, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Axogen, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Axogen, Inc., Globus Medical and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Axogen, Inc.	AXGN	C
Globus Medical, Inc.	GMED	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Axogen, Inc. has a Earnings Estimate Score of 43, which is Neutral. Globus Medical, Inc. has a Earnings Estimate Score of 67, which is Positive.

The Earnings Estimate Revisions Grade Winner: Globus Medical, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Globus Medical, Inc. has a better Earnings Estimate Revisions Grade than Axogen, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Globus Medical, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Axogen, Inc., Globus Medical and Inc. Grades

In addition to Estimate Revisions, Momentum and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Axogen, Inc., Globus Medical and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Axogen, Inc., Globus Medical or Inc. Stock?

Overall, Axogen, Inc. stock has a Value Score of 3, Momentum Score of 92 and Estimate Revisions Score of 43.

Globus Medical, Inc. stock has a Value Score of 49, Momentum Score of 73 and Estimate Revisions Score of 67.

Comparing Axogen, Inc., Globus Medical and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.